Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
NCT05516628Phase 2Recruiting
- Sponsor
- National Cancer Centre Singapore
- Start
- Feb 2023
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by National Cancer Centre Singapore. Started Feb 2023; status: recruiting.
02
Drugs
atezolizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05516628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05516628.